AP-101

Generic Name: AP-101

Brand Names: -

Drug Type: Biotech

Chemical Formula: -

CAS Number: -

Unique Ingredient Identifier: -

Background: AP-101 is a recombinant human antibody directed against human misfolded superoxide dismutase 1.

Associated Conditions: -

Associated Therapies: -

Clinical Trials

·

3 months ago

Targeting Protein Aggregation in ALS

Therapeutic strategies targeting protein aggregation and immune response modulation show promise for ALS and related diseases. Research highlights the role of adaptive immune response, autoimmunity, and protein aggregates in ALS progression. Current therapies, including antibody-based treatments, aim to reduce protein aggregates. Emerging therapies in clinical trials target protein aggregation and immune response modulation, with some showing potential in slowing disease progression.

Related Clinical Trials:

A Study to Evaluate AP-101 in Familial and Sporadic Amyotrophic Lateral Sclerosis (ALS)

A Study to Evaluate, Safety, Tolerability, Pharmacodynamic (PD) Markers and Pharmacokinetics (PK) of AP-101 in Participants With Amyotrophic Lateral Sclerosis (ALS)

Safety, Tolerability, and Exploratory Efficacy Study of Intrathecally Administered Gene Therapy AMT-162 in Adult Participants With SOD1 Amyotrophic Lateral Sclerosis (SOD1-ALS)

FUSION: A Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of ION363 in Amyotrophic Lateral Sclerosis Participants With Fused in Sarcoma Mutations (FUS-ALS)

Colchicine for Amyotrophic Lateral Sclerosis

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DNL343 in Healthy Volunteers

A Study to Determine the Safety, Pharmacokinetics, and Pharmacodynamics of DNL343 in Participants With Amyotrophic Lateral Sclerosis

HEALEY ALS Platform Trial - Regimen G DNL343

Safety and Therapeutic Potential of the FDA-approved Drug Metformin for C9orf72 ALS/FTD

A Double-blind Randomised, Placebo-controlled Clinical Trial to Test Ambroxol Treatment in ALS

Study of WVE-004 in Patients With C9orf72-associated Amyotrophic Lateral Sclerosis (ALS) or Frontotemporal Dementia (FTD)

Prev
1
Next

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy